The optimized formulation of 47.5% w/w of Durotak 87-9301 & 26.5% w/w of Eudragit RL 100 showed sufficient self adhesiveness of prepared patch. The selected formulation also proved the non-irritancy Proteases inhibitor of patch, shows the efficacy of prepared patch in transdermal routes. Optimized formulation provided its possibility to formulate in the area of 5.42 cm2 based on the flux of F9 to attain and maintain desired input rate of FVS over a period of 24 h. All authors have none to declare. “
“Neuropathic pain refers

to pain which originates from a lesion of the nervous system which involve the nociceptive pathways.1 Pain is the most common physical symptom seen within the cancer patients and about 20% of cancer pain syndromes are found to be related to cancer chemotherapy.2 Vincristine is an anti-cancer drug that is widely used in the treatment for leukaemia and lymphoma, which may be accompanied by the serious adverse effect of painful peripheral neuropathic pain which includes hyperalgesia (excessive pain caused by stimulus that is usually nociceptive) and allodynia (a burning pain caused by a stimulus that is not usually nociceptive). Though there exists drugs for treating the cancer chemotherapy induced pain, the relief is not much in context of patient.3 So there exists the learn more need of new treatment regimen which can be used for the treatment of the cancer therapy induced pain. Large-conductance

or BK channels are one type of calcium activated potassium channel which are activated by depolarizing membrane potentials as well as by an increase in the internal calcium concentration. They play an important secondly role in the regulation of neuronal excitability. There is evidence that shows a nerve injury is followed by the suppression of BK channels expression in dorsal root ganglion and the channels are increasingly involved in the control of sensory input in neuropathic pain.4 The activation of BK channels in neurons of rat dorsal root ganglions

leads to a reduced neuronal excitability5 and suggest BK channel openers as a new drug target for neuropathic pain. Cilostazol is a phosphodiesterase III and adenosine uptake inhibitor whose antithrombotic and vasodilator properties have been approved in the United States for reduction of intermittent claudication.6 By virtue of the therapeutic plasma concentrations of Cilostazol ranging from 1 to 5 μM, the BK channel activation may interestingly represent an additional feature of this drug.7 Hence the present study was designed to investigate the effect of Cilostazol, a non-selective BK channel opener drug against the vincristine induced neuropathic pain. Adult albino Swiss mice of either sex weighing 25–35 (g) were used in the pharmacological studies. The inbred animals were taken from the animal house in Vel’s College of Pharmacy, Pallavaram, and Chennai-117. The experiment protocol was approved by the Institutional Animal Ethics Committee IAEC Ref. No. 290/CPCSEA/2009-PH-PCOL-01.